Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTVIREA)

• DTT Name: Adrenergic receptor (ADR)
• Synonyms: Adrenoceptor
• Gene Name: NO-GeName
• DTT Type: Successful target; [1]
• Related Disease:
  Cushing syndrome [ICD-11: 5A70]
  Diagnostic imaging [ICD-11: N.A.]
  Glaucoma [ICD-11: 9C61]
  Hypertension [ICD-11: BA00-BA04]
  Orthostatic hypotension [ICD-11: BA21]
• BioChemical Class: GPCR rhodopsin
• UniProt ID: NOUNIPROTAC
• TTD ID: T15117

Molecular Interaction Atlas (MIA) of This DTT

6 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Befunolol hci	DM8WCXM	Glaucoma/ocular hypertension	9C61	Approved	[2], [3]
Celiprolol HCL	DMD5LBX	Hypertension	BA00-BA04	Approved	[2], [4]
Guanadrel Sulfate	DM6S157	Hypertension	BA00-BA04	Approved	[5]
Ovine corticotropin-releasing hormone	DME0F98	Cushing disease	5A70	Approved	[1]
Oxilofrine	DMRKOS1	Orthostatic hypotension	BA21	Approved	[1]
Terbutyline	DMVPWLZ	Hypertension	BA00-BA04	Approved	[1]

2 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dabelotine	DMP2SGN	Cognitive impairment	6D71	Phase 3	[6]
AR08	DM93CTQ	Attention deficit hyperactivity disorder	6A05.Z	Phase 2	[7]

1 Patented Agent(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID30124346-Compound-60TABLE5	DM3QX0R	Dyskinesia	MB47.4	Patented	[8]

2 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Etilefrine	DM67PWD	Cardiovascular disease	BA00-BE2Z	Withdrawn from market	[1]
AIR-Epinephrine	DMGAERX	Allergy	4A80-4A85	Discontinued in Phase 1	[9]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [3] Enzyme immunoassays for beta-adrenoreceptor blocking agent, befunolol and its main metabolite, M1. J Immunoassay. 1983;4(4):351-71.
• [4] Celiprolol: a new beta adrenoceptor antagonist with novel ancillary properties. J Cardiovasc Pharmacol. 1986;8 Suppl 4:S29-32.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] US patent application no. 2007,0049,576, Neurogenesis by muscarinic receptor modulation.
• [7] Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov. 2014 June; 9(6): 579-594.
• [8] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [9] Prostaglandin synthesis inhibitors reverse alpha-adrenergic inhibition of acute insulin response to glucose. Am J Physiol. 1980 Dec;239(6):E490-500.